Search

Displaying results 641 - 650 of 9686 in total
  1. Drug

    IGN101

    go.drugbank.com/drugs/DB06500
    Experimental

    It consists of 500 ug 17-1A antibody adsorbed on aluminum hydroxide.

  2. Drug

    Vilobelimab

    go.drugbank.com/drugs/DB16416
    ApprovedInvestigational

    Vilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity. … It consists of mouse anti-human complement factor 5a (C5a) monoclonal binding sites (variable regions of heavy and light chain regions) and human gamma 4 heavy chain and light kappa chain constant regions

  3. Drug

    Cyclosporine

    go.drugbank.com/drugs/DB00091
    ApprovedInvestigationalVet approved

    Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions.

    Categories: BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: Cyclosporin A, Cyclosporine A
  4. Drug

    Atomoxetine

    go.drugbank.com/drugs/DB00289
    ApprovedInvestigational

    [A178090] Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. … Many contain a blackbox warning stating that CNS stimulants, including methylphenidate-containing products and amphetamines, have a high potential for abuse and dependence.

    Products: ATOMOXE 1A PHARMA 10MG, ATOMOXE 1A PHARMA 18MG
  5. Drug

    LY-517717

    go.drugbank.com/drugs/DB05713
    Investigational

    LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).

  6. Drug

    Empagliflozin

    go.drugbank.com/drugs/DB09038
    ApprovedInvestigational

    Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combinatio...

  7. Drug

    Imlifidase

    go.drugbank.com/drugs/DB15258
    ApprovedInvestigational

    Chronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant burden for both the individual and healthcare system at large. … to non-self HLA antigens, face additional barriers to transplantation.

  8. Drug

    Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10296
    ApprovedInvestigational

    * serotype 6a individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197). … Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae

    Synonyms: Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine, Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
  9. Drug

    Drotrecogin alfa

    go.drugbank.com/drugs/DB00055
    ApprovedWithdrawn

    It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. … Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.

  10. Drug

    Abetimus

    go.drugbank.com/drugs/DB06662
    Investigational

    Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.